Search

Carlos Bais Phones & Addresses

  • Bethesda, MD
  • 136 Harvard St, San Francisco, CA 94134
  • 347 Richland Ave, San Francisco, CA 94110 (415) 826-9376
  • 549 Riverside Blvd, New York, NY 10027 (917) 493-9453
  • 549 Riverside Dr APT 4F, New York, NY 10027 (212) 493-9453

Work

Position: Executive, Administrative, and Managerial Occupations

Education

Degree: Associate degree or higher

Resumes

Resumes

Carlos Bais Photo 1

Director

View page
Location:
South San Francisco, CA
Industry:
Biotechnology
Work:
Genentech
Director

Genentech
Biomarker Group Leader and Principal Scientist

Medimmune Jan 1, 2016 - Jun 2017
Director R and D, Translational Medicine Oncology

Genentech Jan 2013 - Nov 2015
Senior Scientist-Principal Scientist Biomarker Leader, Oncology Biomarker Development

Genentech Sep 2005 - Dec 2012
Scientist-Senior Scientist, Research
Education:
University of Buenos Aires
Master of Science, Doctorates, Masters, Doctor of Philosophy, Molecular Biology
Skills:
Biomarkers
Oncology
Drug Development
Translational Research
Antibodies
Biomarker Discovery
Life Sciences
Translational Medicine
Drug Discovery
Cell Biology
Cell Signaling
Signal Transduction
Assay Development
Monoclonal Antibodies
Cell
Biotechnology
Research Oncologist
Tumor Angiogenesis
Angiogenesis
Molecular Biology
More Than Six Years of Industry and Drug Development Experience
Therapeutic Antibody Development
Elucidation of Mechanism of Action of Targeted Drugs
Consistent Track Record of Publication In Top Tier Journals
Languages:
Spanish
English
Carlos Bais Photo 2

Carlos Bais

View page
Location:
United States

Publications

Us Patents

Anti-Plgf Antibodies And Methods Using Same

View page
US Patent:
20110171231, Jul 14, 2011
Filed:
Jan 12, 2011
Appl. No.:
13/005067
Inventors:
Carlos Bais - South San Francisco CA, US
Krista McCutcheon - South San Francisco CA, US
International Classification:
A61K 39/395
C07K 16/00
C07H 21/00
A61P 35/00
A61P 31/18
C12N 15/63
C12N 5/10
C12P 21/00
G01N 33/53
US Classification:
4241581, 5303892, 5303881, 5303873, 536 2353, 4353201, 435325, 435 696, 436501
Abstract:
The invention provides anti-PlGF antibodies and methods of using the same.

Biological Markers For Monitoring Patient Response To Vegf Antagonists

View page
US Patent:
20110117083, May 19, 2011
Filed:
Aug 13, 2010
Appl. No.:
12/856394
Inventors:
Carlos Bais - San Francisco CA, US
Mallika Singh - San Francisco CA, US
Joshua Kaminker - San Francisco CA, US
Matthew Brauer - San Francisco CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39/395
C12Q 1/68
G01N 33/53
C40B 30/04
A61P 35/00
US Classification:
4241331, 435 6, 4241581, 435 792, 506 9
Abstract:
The invention provides methods and compositions to detect expression of one or more biomarkers for monitoring the effectiveness of treatment of with VEGF antagonists. The invention also provides methods for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.

Tumor Burden As Measured By Cell Free Dna

View page
US Patent:
20180282417, Oct 4, 2018
Filed:
Mar 30, 2018
Appl. No.:
15/941358
Inventors:
- Gaithersburg MD, US
Koustubh Ranade - Gaithersburg MD, US
Carlos Bais - Gaithersburg MD, US
Philip Brohawn - Gaithersburg MD, US
Michael Kuziora - Gaithersburg MD, US
Rajiv Raja - Gaithersburg MD, US
International Classification:
C07K 16/28
C12Q 1/6886
Abstract:
Disclosed are methods for treating cancer (e.g., solid tumor cancers, lung cancer, bladder head and neck cancer) with an anti-PD-L1 antibody in a patient identified as being responsive to anti-PD-L1 antibody therapy by detecting a mutation in one or more disclosed circulating tumor DNA (ctDNA) markers. Also disclosed are methods for determining the efficacy of anti-PD-L1 therapeutic antibody treatment in a patient having lung cancer or bladder cancer comprising detecting variant allele frequency in ctDNA in plasma samples and determining the difference of the variant allele frequency in ctDNA between the first and at least second plasma samples, wherein a decrease in the variant allele frequency in the at least second plasma sample relative to the first plasma sample identifies the anti-PD-L1 antibody treatment as effective. The disclosure also provides methods of identifying a subject having a cancer responsive to a therapy comprising an anti-PD-L1 antibody by detecting the expression of a mutation in one or more circulating tumor DNA (ctDNA) markers.

Predicting Response To A Vegf Antagonist

View page
US Patent:
20170226198, Aug 10, 2017
Filed:
Apr 28, 2017
Appl. No.:
15/581448
Inventors:
- South San Francisco CA, US
Carlos BAIS - South San Francisco CA, US
YounJeong CHOI - South San Francisco CA, US
Nicola C. CONSALVO - Basel, CH
International Classification:
C07K 16/22
A61K 39/395
G01N 33/574
A61K 31/495
A61K 38/21
C07K 16/30
A61K 45/06
Abstract:
The invention describes the use of high CD31 and/or tumor VEGFA as selection criteria for determining patient benefit or responsiveness to a VEGF antagonist, such as bevacizumab. The present invention also describes the use of high CD31 and/or tumor VEGFA as a selection criterion for treating cancer patients, such as ovarian cancer patients, who are undergoing a chemotherapy and/or anti-cancer therapy regimen, with a VEGF antagonist, such as bevacizumab.
Carlos E Bais from Bethesda, MD, age ~56 Get Report